Vir Biotechnology (VIR) Share-based Compensation (2018 - 2026)

Vir Biotechnology's Share-based Compensation history runs 9 years deep, the most recent figure standing at $12.1 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 14.03% year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $47.1 million (down 31.5% YoY), while the FY2025 annual figure was $49.1 million, down 37.45% from the prior year.
• Share-based Compensation came in at $12.1 million for Q1 2026 at Vir Biotechnology, up from $11.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $30.6 million in Q2 2023 to a low of $11.2 million in Q4 2025.
• A 5-year average of $20.8 million and a median of $23.8 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 63.56% in 2022 and plunged 43.97% in 2024, its largest moves.
• Vir Biotechnology's Share-based Compensation stood at $24.9 million in 2022, then climbed by 13.7% to $28.3 million in 2023, then tumbled by 43.97% to $15.8 million in 2024, then retreated by 29.26% to $11.2 million in 2025, then increased by 7.86% to $12.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $12.1 million, $11.2 million, and $11.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison